Osimertinib was originally approved as a second-line EGFR-TKI for patients with lung cancer with EGFR mutations that acquired resistance to first or second-generation EGFR-TKIs through the T790M secondary mutation. This evidence concerns the gene EGFR and lung carcinoma.